Study of plonmarlimab for frequent gout attacks
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Pain clinical trials.
This trial tests a new investigational drug called plonmarlimab for people with frequent, painful gout flares who cannot take standard treatments. The goal is to see if it can reduce pain and inflammation from the flare.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have had a gout flare in the last 5 days.
- You have had at least 3 gout flares in the last year.
- You cannot take or colchicine or NSAIDs (like ibuprofen) did not work for you.
- Your pain during the flare is at least 50 on a 0-100 scale (0=no pain, 100=worst pain).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for people with sudden gout flare-ups who haven't gotten relief from or can't take the usual treatments. It may help reduce pain and inflammation faster, and you'll receive either the study drug or a placebo (inactive treatment) along with standard care.
This trial tests a new medication, ABP-745, for people having an acute gout flare. It aims to see if the drug is safe and helps reduce pain and inflammation.
This trial tests an oral medication (HRS-2129) to see if it can calm a sudden gout flare and reduce joint pain. It may help if you are currently having a moderate-to-severe gout attack and are otherwise in good health.
This trial tests a new treatment called plamotamab for people with moderate to severe rheumatoid arthritis (RA) who have not had enough relief from current treatments. The goal is to see if it is safe and to help control RA symptoms.
This study tests a medicine called SSGJ-613 to see if it can reduce gout flares when people start treatment to lower uric acid. It may help people who have frequent gout attacks.
This trial tests a new drug called plonmarlimab for people with a rheumatic (joint or immune) disease who also have a dangerous overreaction of their immune system called HLH (or MAS). The goal is to see if the drug can help when high-dose steroids have not worked or are not an option.
Hear when a new Acute Gouty Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.